Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Intratumoral immunotherapy can potentially modulate the tumor microenvironment (TME) and potentiate the effects of concomitant or sequential systemic immunotherapies. Intratumoral administration of different Toll-like receptor agonists, including TLR4, can potentiate these effects through innate and adaptive immunity connection.See related article by Bhatia et al., p. 1185.

Original publication

DOI

10.1158/1078-0432.ccr-18-2690

Type

Journal article

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Publication Date

02/2019

Volume

25

Pages

1127 - 1129

Addresses

Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain. ivanpantic@hotmail.com.

Keywords

Humans, Carcinoma, Merkel Cell, Skin Neoplasms, Immunotherapy, Toll-Like Receptor 4, Adaptive Immunity, Tumor Microenvironment